TY - JOUR
T1 - Serum microRNAs are promising novel biomarkers
AU - Gilad, Shlomit
AU - Meiri, Eti
AU - Yogev, Yariv
AU - Benjamin, Sima
AU - Lebanony, Danit
AU - Yerushalmi, Noga
AU - Benjamin, Hila
AU - Kushnir, Michal
AU - Cholakh, Hila
AU - Melamed, Nir
AU - Bentwich, Zvi
AU - Hod, Moshe
AU - Goren, Yaron
AU - Chajut, Ayelet
N1 - Funding Information:
Rosetta Genomics is a commercial for-profit company. Most key investigators are employees of the company. MH receives research and personal funding from Rosetta Genomics.
PY - 2008/9/5
Y1 - 2008/9/5
N2 - Background: Circulating nucleic acids (CNAs) offer unique opportunities for early diagnosis of clinical conditions. Here we show that microRNAs, a family of small non-coding regulatory RNAs involved in human development and pathology, are present in bodily fluids and represent new effective biomarkers. Methods and Results: After developing protocols for extracting and quantifying microRNAs in serum and other body fluids, the serum microRNA profiles of several healthy individuals were determined and found to be similar, validating the robustness of our methods. To address the possibility that the abundance of specific microRNAs might change during physiological or pathological conditions, serum microRNA levels in pregnant and non pregnant women were compared. In sera from pregnant women, microRNAs associated with human placenta were significantly elevated and their levels correlated with pregnancy stage. Conclusions and Significance: Considering the central role of microRNAs in development and disease, our results highlight the medically relevant potential of determining microRNA levels in serum and other body fluids. Thus, microRNAs are a new class of CNAs that promise to serve as useful clinical biomarkers.
AB - Background: Circulating nucleic acids (CNAs) offer unique opportunities for early diagnosis of clinical conditions. Here we show that microRNAs, a family of small non-coding regulatory RNAs involved in human development and pathology, are present in bodily fluids and represent new effective biomarkers. Methods and Results: After developing protocols for extracting and quantifying microRNAs in serum and other body fluids, the serum microRNA profiles of several healthy individuals were determined and found to be similar, validating the robustness of our methods. To address the possibility that the abundance of specific microRNAs might change during physiological or pathological conditions, serum microRNA levels in pregnant and non pregnant women were compared. In sera from pregnant women, microRNAs associated with human placenta were significantly elevated and their levels correlated with pregnancy stage. Conclusions and Significance: Considering the central role of microRNAs in development and disease, our results highlight the medically relevant potential of determining microRNA levels in serum and other body fluids. Thus, microRNAs are a new class of CNAs that promise to serve as useful clinical biomarkers.
UR - http://www.scopus.com/inward/record.url?scp=52349083651&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0003148
DO - 10.1371/journal.pone.0003148
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 18773077
AN - SCOPUS:52349083651
SN - 1932-6203
VL - 3
JO - PLoS ONE
JF - PLoS ONE
IS - 9
M1 - e3148
ER -